Original article by Carrie LaFrenz
The Australian Financial Review – Page: 1 & 6 : 4-Jan-19

Shares in pathology, imaging and medical centres operator Healius closed 7.8 per cent higher at $2.63 on 3 January, in response to a takeover bid from Jangho Group. The Chinese company already has a 15.93 per cent stake in Healius and is offering $3.25 per share. Healius, which changed its name from Primary Health Care in late 2018, has advised shareholders to take no action regarding the unsolicited offer at present. It has stressed that Jangho’s approach may not necessarily result in a deal.

CORPORATES
HEALIUS LIMITED – ASX HLS, JANGHO GROUP, VISION EYE INSTITUTE LIMITED, MONASH IVF GROUP LIMITED – ASX MVF, HEALTHSCOPE LIMITED – ASX HSO, MACQUARIE GROUP LIMITED – ASX MQG, CHEUNG KONG INFRASTRUCTURE HOLDINGS LIMITED, APA GROUP – ASX APA, HUAWEI TECHNOLOGIES COMPANY LIMITED, AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED – ASX API, SIGMA HEALTHCARE LIMITED – ASX SIG, AUSTRALIA. FOREIGN INVESTMENT REVIEW BOARD, AUSTRALIAN SECURITIES AND INVESTMENTS COMMISSION, AUSTRALIA. FAIR WORK COMMISSION, KING AND WOOD MALLESONS, UBS HOLDINGS PTY LTD